Goldschmidt, Hartmut http://orcid.org/0000-0003-0961-0035
Baertsch, Marc-Andrea http://orcid.org/0000-0002-4000-6904
Schlenzka, Jana
Becker, Natalia
Habermehl, Christina
Hielscher, Thomas
Raab, Marc-Steffen
Hillengass, Jens
Sauer, Sandra
Müller-Tidow, Carsten http://orcid.org/0000-0002-7166-5232
Luntz, Steffen
Jauch, Anna
Hose, Dirk
Seckinger, Anja
Brossart, Peter
Goerner, Martin
Klein, Stefan
Schmidt-Hieber, Martin
Reimer, Peter
Graeven, Ullrich
Fenk, Roland
Haenel, Mathias
Martin, Hans
Lindemann, Hans W.
Scheid, Christoph
Nogai, Axel
Salwender, Hans
Noppeney, Richard
Besemer, Britta
Weisel, Katja
,
Article History
Received: 12 April 2020
Revised: 20 June 2020
Accepted: 23 June 2020
First Online: 21 July 2020
Compliance with ethical standards
:
: HG—Amgen: consultancy, research funding; Novartis: honoraria, research funding; ArtTempi: honoraria; Janssen: consultancy, honoraria, research funding; Sanofi: consultancy, research funding; Mundipharma: research funding; Takeda: consultancy, research funding; Celgene: consultancy, honoraria, research funding; Bristol-Myers Squibb: consultancy, honoraria, research funding; Adaptive Biotechnology: consultancy; Chugai: honoraria, research funding. MAB—Takeda: consultancy, honoraria; Novartis: consultancy, research funding. Travel support: Celgene, Amgen, and Janssen. M-SB: Celgene: consultancy, honoraria; Novartis: consultancy, honoraria, research funding; BMS: consultancy, honoraria, research funding; Amgen: consultancy, honoraria, research funding. JH—Janssen: honoraria, advisory board; Amgen: advisory board; BMS: honoraria, advisory board, research funding; Oncotracker: advisory board; Adaptive Biotech: advisory board; GSK: advisory board. Celgene: consultancy, honoraria, Other: advisory board, research funding. CM-T—research funding: Pfizer, Daiichi Sankyo, BiolineRx, Bayer; advisory boards: Pfizer, Janssen. MS-H—consultancy: Celgene; financial support of educational meetings: Janssen, Takeda, Novartis, Pfizer, Roche, Vifor, Celgene. PR—Honoraria: Takeda, BMS, Roche, Celgene, Sanofi-Aventis; travel support: Celgene, Takeda, Abbvie. UG—honoraria: Sirtex, Daiichi Sankyo, Boehringer Ingelheim, Amgen, Servier, AstraZeneca; consultancy, advisory boards: Merck, BMS, Hexal, Amgen, Celgene, Johnson & Johnson, MSD; travel support: Merck, Amgen, Boehringer Ingelheim. RF—Takeda: honoraria; Bristol-Meyers Squibb: honoraria, Other: travel grant; Celgene: honoraria, Other: travel grant, research funding; Janssen: honoraria; Amgen: honoraria. MH—Novartis: honoraria; Roche: honoraria; Amgen: honoraria; Takeda: honoraria. CS—Novartis: honoraria, research funding; Takeda: honoraria, research funding; Janssen: honoraria, research funding; Celgene: honoraria; BMS: honoraria; Amgen: honoraria; GSK: honoraria. AN—honoraria: Celgene, Takeda, Amgen, Alexion, Sanofi, Janssen, BMS. Research funding: Celgene, Janssen, Takeda. Travel support: Celgene, Takeda, Alexion. HS—Celgene: honoraria, Other: travel suppport, research funding; Janssen: honoraria, Other: travel support, research funding; Novartis: honoraria, Other: travel suppport, research funding; Takeda: honoraria; Amgen: honoraria, Other: travel suppport, research funding; Bristol-Myers Squibb: honoraria, Other: travel suppport, research funding. BB—Janssen: honoraria. KW—Amgen, Celgene, Janssen, and Sanofi: research funding; Amgen, BMS, Celgene, Janssen, Takeda, Adaptive Biotech: honoraria; Amgen, Adaptive Biotech, BMS, Celgene, Janssen, Juno, Sanofi, GSK, Karyopharm and Takeda: consultancy, membership on an entity’s Board of Directors or advisory committees.